Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30,373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers.
Rubinstein MP, Williams C, Mart C, Beall J, MacPherson L, Azar J, Swiderska-Syn M, Manca P, Gibney BC, Robinson MD, Krieg C, Hill EG, Taha SA, Rock AD, Lee JH, Soon-Shiong P, Wrangle J. Rubinstein MP, et al. Among authors: lee jh. J Immunol. 2022 Mar 15;208(6):1362-1370. doi: 10.4049/jimmunol.2100066. Epub 2022 Feb 28. J Immunol. 2022. PMID: 35228263 Clinical Trial.
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial.
Miller JS, Davis ZB, Helgeson E, Reilly C, Thorkelson A, Anderson J, Lima NS, Jorstad S, Hart GT, Lee JH, Safrit JT, Wong H, Cooley S, Gharu L, Chung H, Soon-Shiong P, Dobrowolski C, Fletcher CV, Karn J, Douek DC, Schacker TW. Miller JS, et al. Among authors: lee jh. Nat Med. 2022 Feb;28(2):392-400. doi: 10.1038/s41591-021-01651-9. Epub 2022 Jan 31. Nat Med. 2022. PMID: 35102335 Clinical Trial.
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Foltz JA, et al. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 8. Clin Cancer Res. 2021. PMID: 33832946 Free PMC article. Clinical Trial.
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Lee KL, Benz SC, Hicks KC, Nguyen A, Gameiro SR, Palena C, Sanborn JZ, Su Z, Ordentlich P, Rohlin L, Lee JH, Rabizadeh S, Soon-Shiong P, Niazi K, Schlom J, Hamilton DH. Lee KL, et al. Among authors: lee jh. Cancer Immunol Res. 2019 Aug;7(8):1359-1370. doi: 10.1158/2326-6066.CIR-18-0620. Epub 2019 Jul 10. Cancer Immunol Res. 2019. PMID: 31292145 Free PMC article.
A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells.
Cubitt CC, McClain E, Becker-Hapak M, Foltz JA, Wong P, Wagner JA, Neal CC, Marin ND, Marsala L, Foster M, Schappe T, Soon-Shiong P, Lee J, Berrien-Elliott MM, Fehniger TA. Cubitt CC, et al. Mol Ther Oncolytics. 2022 Feb 15;24:585-596. doi: 10.1016/j.omto.2022.02.009. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35284622 Free PMC article.
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, Padget MR, Abdul Sater H, Lee JH, Soon-Shiong P, Gulley J, Schlom J, Hodge JW, Allen CT. Robbins Y, et al. Among authors: lee jh. Elife. 2020 Jul 7;9:e54854. doi: 10.7554/eLife.54854. Elife. 2020. PMID: 32633234 Free PMC article.
Correction to: Immunotherapy Utilizing the Combination of Natural Killer- and Antibody Dependent Cellular Cytotoxicity (ADCC)-Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition.
Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW. Fenerty KE, et al. Among authors: lee jh. J Immunother Cancer. 2019 Sep 2;7(1):234. doi: 10.1186/s40425-019-0715-9. J Immunother Cancer. 2019. PMID: 31477176 Free PMC article.
30,373 results
You have reached the last available page of results. Please see the User Guide for more information.